Welcome to our dedicated page for Liquidia Corporation news (Ticker: LQDA), a resource for investors and traders seeking the latest updates and insights on Liquidia Corporation stock.
Liquidia Corporation (LQDA) is a biopharmaceutical innovator leveraging its proprietary PRINT® Technology to develop precision therapies for pulmonary hypertension and rare cardiopulmonary conditions. This page aggregates official company announcements, providing stakeholders with timely updates on clinical advancements, regulatory milestones, and strategic initiatives.
Investors and researchers will find curated press releases detailing progress in Liquidia’s pipeline, including YUTREPIA™ inhalation powder development, FDA communications, and technology licensing agreements. Content spans clinical trial results, manufacturing updates, and partnership announcements with global pharmaceutical entities.
Key categories include treatment efficacy studies, regulatory filings, intellectual property developments, and operational expansions. All materials adhere to factual reporting standards, ensuring reliable insights into the company’s scientific and business trajectory.
Bookmark this page for streamlined access to Liquidia’s latest verified updates. Combine regular visits with professional financial counsel to inform your investment strategy.
Liquidia Corporation (NASDAQ: LQDA) achieved a favorable ruling from the U.S. Patent Trial and Appeal Board (PTAB) in its patent dispute with United Therapeutics Corporation. The PTAB deemed seven of the nine claims of U.S. Patent No. 9,604,901 unpatentable, leaving only narrower claims 6 and 7. This decision does not resolve ongoing litigation under the Hatch-Waxman Act regarding LIQ861, an investigational treatment for pulmonary arterial hypertension. Liquidia aims to commercialize LIQ861 following resolution of the litigation.
Liquidia Corporation (NASDAQ: LQDA) announced that CEO Damian deGoa will present at the H.C. Wainwright 23rd Annual Global Investment Conference, scheduled for September 13-15, 2021. The presentation will be virtual and available on-demand in the Investors section of Liquidia's website starting at 7:00 a.m. ET on September 13, 2021. It will remain accessible for 30 days post-conference. Liquidia focuses on the development of products for pulmonary hypertension using its PRINT® Technology.
Liquidia Corporation (NASDAQ: LQDA) announced that the FDA has completed a Pre-Approval Inspection (PAI) of its Morrisville, NC facility for the New Drug Application (NDA) of LIQ861 (treprostinil) inhalation powder. The inspection, which lasted five days and concluded on August 13, resulted in no Form 483 observations, marking a positive milestone for the company. The NDA, resubmitted on June 2, includes necessary clarifications and is under FDA review, with a PDUFA goal date set for November 7, 2021. The inspection supports Liquidia's proprietary PRINT® technology for enhanced drug delivery.
Liquidia Corporation (NASDAQ: LQDA) announced that the U.S. Patent Trial and Appeal Board (PTAB) has initiated inter partes review (IPR) of United Therapeutics' U.S. Patent No. 10,716,793. The PTAB indicated a reasonable likelihood of Liquidia succeeding in demonstrating the patent's unpatentability. This development could advance Liquidia's efforts to introduce LIQ861, an inhaled dry powder formulation of treprostinil, to treat pulmonary arterial hypertension (PAH). The FDA is reviewing the LIQ861 New Drug Application with a goal date set for November 7, 2021.
Liquidia Corporation (NASDAQ: LQDA) announced significant developments in its recent press release. It launched subcutaneous delivery of Treprostinil Injection, effectively doubling the market potential for this treatment. The company has also resubmitted its New Drug Application (NDA) for LIQ861, which received FDA acceptance for review, with a PDUFA goal date set for November 7, 2021. Financially, Liquidia has improved its balance sheet, reducing annual spending and increasing cash resources to $67.9 million as of June 30, 2021, while reporting revenue of $3.4 million in Q2 2021.
Liquidia Corporation (NASDAQ: LQDA) will report its second quarter 2021 financial results on August 10, 2021. A conference call and webcast are scheduled for 8:30 a.m. EDT, where the company will discuss financial outcomes and provide a corporate update. Interested parties can access the call via telephone or the webcast available on Liquidia's website. The company focuses on developing treatments for pulmonary hypertension through its PRINT® Technology, with ongoing projects like LIQ861 and Treprostinil Injection.
On June 7, 2021, United Therapeutics Corporation (Nasdaq: UTHR) announced it is pursuing trade secret misappropriation claims against Liquidia Technologies, Inc. (Nasdaq: LQDA) and a former employee. The lawsuit stems from evidence suggesting the employee took confidential documents to Liquidia during the development of LIQ861, a product competing with United Therapeutics' Tyvaso. The FDA's approval of LIQ861 is on hold pending the outcome of the litigation, which is scheduled for trial in March 2022. United Therapeutics seeks monetary and injunctive relief due to these allegations.
Liquidia Corporation (NASDAQ: LQDA) announced on June 2, 2021, that the FDA accepted its New Drug Application (NDA) resubmission for LIQ861, an inhalation powder for treating pulmonary arterial hypertension (PAH). The resubmission is a complete, class 2 response to a prior FDA action letter from November 24, 2020. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of November 7, 2021, for potential approval. However, final approval may be subject to ongoing legal issues with United Therapeutics and a regulatory stay that ends in October 2022.
Liquidia Corporation (NASDAQ: LQDA) announced that CEO Damian deGoa will present at the Jefferies Virtual Healthcare Conference on June 2, 2021, from 2:30 to 2:55 p.m. EDT. The session aims to provide an overview and update on the company's business strategies and developments. Investors and interested parties can access the live webcast through the Liquidia website, and an archived version will be available for 90 days post-event. Liquidia is focused on developing treatments for pulmonary hypertension using its proprietary PRINT® Technology.
Liquidia Corporation announced the availability of Sandoz Treprostinil Injection, a generic version of Remodulin®, for both subcutaneous and intravenous administration to treat pulmonary arterial hypertension (PAH). This is the first fully-substitutable generic option, providing lower-cost treatment alternatives. The RG 3ml Medication Cartridge has been cleared by the FDA, allowing for the SC administration of the medication, previously restricted. Liquidia aims to maintain high support levels while offering competitive pricing for patients.
FAQ
What is the current stock price of Liquidia Corporation (LQDA)?
What is the market cap of Liquidia Corporation (LQDA)?
